Epigenetic Mechanisms in Sepsis-Associated Acute Kidney Injury

Marco Fiorentino; Reginald Philippe; Carmen A. Palumbo; Stefania Prenna; Vincenzo Cantaluppi; Silva De Rosa

doi:10.1055/s-0044-1789240

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2024; 45(04): 491-502
DOI: 10.1055/s-0044-1789240

Review Article

Epigenetic Mechanisms in Sepsis-Associated Acute Kidney Injury

Autoren

Marco Fiorentino

¹Nephrology, Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro,” Bari, Italy
Reginald Philippe

²Centre for Medical Sciences - CISMed, University of Trento, Trento, Italy
Carmen A. Palumbo

¹Nephrology, Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro,” Bari, Italy
Stefania Prenna

³Department of Anesthesia and Intensive Care, Santa Chiara Hospital, APSS Trento, Trento, Italy
Vincenzo Cantaluppi

⁴Nephrology and Kidney Transplantation Unit, Department of Translational Medicine (DIMET), University of Piemonte Orientale (UPO), “Maggiore della Carità” University Hospital, Novara, Italy
Silva De Rosa

²Centre for Medical Sciences - CISMed, University of Trento, Trento, Italy

Abstract

Sepsis, the dysregulated immune response of the host to infections, leads to numerous complications, including multiple organ dysfunction with sepsis-associated acute kidney injury (SA-AKI) being a frequent complication associated with increased risk of mortality and the progression toward chronic kidney disease (CKD). Several mechanisms have been widely investigated in understanding the complex pathophysiology of SA-AKI, including hemodynamic alterations, inflammation, oxidative stress, and direct cellular injury driven by pathogens or cell-derived products (pathogen-associated molecular patterns and damage-associated molecular patterns). Despite advancements in the management of septic patients, the prognosis of SA-AKI patients remains significantly poor and is associated with high in-hospital mortality and adverse long-term outcomes. Therefore, recent research has focused on the early identification of specific SA-AKI endotypes and subphenotypes through epigenetic analysis and the use of potential biomarkers, either alone or in combination with clinical data, to improve prognosis. Epigenetic regulation, such as DNA methylation, histone modifications, and noncoding RNA modulation, is crucial in modulating gene expression in response to stress and renal injury in SA-AKI. At the same time, these modifications are dynamic and reversible processes that can alter gene expression in several pathways implicated in the context of SA-AKI, including inflammation, immune response, and tolerance status. In addition, specific epigenetic modifications may exacerbate renal damage by causing persistent inflammation or cellular metabolic reprogramming, leading to progression toward CKD. This review aims to provide a comprehensive understanding of the epigenetic characteristics that define SA-AKI, also exploring targeted therapies that can improve patient outcomes and limit the chronic progression of this syndrome.

Keywords

sepsis - acute kidney injury - epigenetics - inflammation - biomarkers - renal replacement therapy

Volltext

Referenzen

References
1 Cao M, Wang G, Xie J. Immune dysregulation in sepsis: experiences, lessons and perspectives. Cell Death Discov 2023; 9 (01) 465
2 Singer M, Deutschman CS, Seymour CW. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (08) 801-810
3 Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120 (04) c179-c184
4 Fiorentino M, Tohme FA, Wang S, Murugan R, Angus DC, Kellum JA. Long-term survival in patients with septic acute kidney injury is strongly influenced by renal recovery. PLoS One 2018; 13 (06) e0198269
5 Franzin R, Stasi A, Sallustio F. et al. Extracellular vesicles derived from patients with antibody-mediated rejection induce tubular senescence and endothelial to mesenchymal transition in renal cells. Am J Transplant 2022; Sep; 22 (09) 2139-2157
6 Matsuura R, Doi K, Rabb H. Acute kidney injury and distant organ dysfunction-network system analysis. Kidney Int 2023; Jun; 103 (06) 1041-1055
7 Coca SG, Vasquez-Rios G, Mansour SG. et al. Plasma soluble tumor necrosis factor receptor concentrations and clinical events after hospitalization: findings from the ASSESS-AKI and ARID studies. Am J Kidney Dis 2023; 81 (02) 190-200
8 See EJ, Jayasinghe K, Glassford N. et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int 2019; 95 (01) 160-172
9 Hoste E, Bihorac A, Al-Khafaji A. et al; RUBY Investigators. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med 2020; 46 (05) 943-953
10 Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81 (05) 442-448
11 Baeseman L, Gunning S, Koyner JL. Biomarker enrichment in sepsis-associated acute kidney injury: finding high-risk patients in the intensive care unit. Am J Nephrol 2024; 55 (01) 72-85
12 Wang Q, Liu F, Tao W, Qian K. Timing of renal replacement therapy in patients with sepsis-associated acute kidney injury: a systematic review and meta-analysis. Aust Crit Care 2024; 37 (02) 369-379
13 De Rosa S, Marengo M, Fiorentino M. et al; SIAARTI-SIN joint commission. Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission. J Nephrol 2023; 36 (07) 1731-1742
14 Ronco C, Tetta C, Mariano F. et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003; 27 (09) 792-801
15 Guo C, Dong G, Liang X, Dong Z. Epigenetic regulation in AKI and kidney repair: mechanisms and therapeutic implications. Nat Rev Nephrol 2019; 15 (04) 220-239
16 Wu YL, Lin ZJ, Li CC. et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduct Target Ther 2023; 8 (01) 98
17 Zhang Q, Cao X. Epigenetic regulation of the innate immune response to infection. Nat Rev Immunol 2019; 19 (07) 417-432
18 Pillitteri M, Brogi E, Piagnani C, Forfori F. Pathophysiology of endotoxic shock. In: De Rosa S, Villa G. eds. Endotoxin Induced-Shock: A Multidisciplinary Approach in Critical Care. Springer International Publishing; 2023: 13-22
19 Rogovskii V. Immune tolerance as the physiologic counterpart of chronic inflammation. Front Immunol 2020; 11: 2061
20 Sabogal-Guáqueta AM, Marmolejo-Garza A, Trombetta-Lima M. et al. Species-specific metabolic reprogramming in human and mouse microglia during inflammatory pathway induction. Nat Commun 2023; 14 (01) 6454
21 Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology 2013; 38 (01) 23-38
22 Bommarito PA, Fry RC. The role of DNA methylation in gene regulation. In: Toxicoepigenetics. Elsevier; 2019: 127-151
23 Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293 (5532): 1068-1070
24 Xie Y, Liu B, Pan J. et al. MBD2 mediates septic AKI through activation of PKCη/p38MAPK and the ERK1/2 axis. Mol Ther Nucleic Acids 2020; 23: 76-88
25 Sun T, Liu Q, Wang Y, Deng Y, Zhang D. MBD2 mediates renal cell apoptosis via activation of Tox4 during rhabdomyolysis-induced acute kidney injury. J Cell Mol Med 2021; 25 (10) 4562-4571
26 Wang J, Li H, Qiu S, Dong Z, Xiang X, Zhang D. MBD2 upregulates miR-301a-5p to induce kidney cell apoptosis during vancomycin-induced AKI. Cell Death Dis 2017; 8 (10) e3120-e3120
27 Shih CC, Liao MH, Hsiao TS. et al. Procainamide inhibits DNA methylation and alleviates multiple organ dysfunction in rats with endotoxic shock. PLoS One 2016; 11 (09) e0163690
28 Binnie A, Walsh CJ, Hu P. et al; Epigenetic Profiling in Severe Sepsis (EPSIS) Study of the Canadian Critical Care Translational Biology Group (CCCTBG). Epigenetic profiling in severe sepsis: a pilot study of DNA methylation profiles in critical illness. Crit Care Med 2020; 48 (02) 142-150
29 Emblem Å, Knutsen E, Jørgensen TE. et al. Blood transcriptome analysis of septic patients reveals a long non-coding Alu-RNA in the complement C5a receptor 1 gene. Noncoding RNA 2022; 8 (02) 24
30 Papathanakos G, Andrianopoulos I, Xenikakis M. et al. Clinical sepsis phenotypes in critically ill patients. Microorganisms 2023; 11 (09) 2165
31 Cavalieri V. The expanding constellation of histone post-translational modifications in the epigenetic landscape. Genes (Basel) 2021; 12 (10) 1596
32 Peixoto P, Cartron PF, Serandour AA, Hervouet E. From 1957 to nowadays: a brief history of epigenetics. Int J Mol Sci 2020; 21 (20) 7571
33 Zhang Y, Sun Z, Jia J. et al. Overview of histone modification. In: Fang D, Han J. eds. Histone Mutations and Cancer, Vol. 1283. Advances in Experimental Medicine and Biology. Springer Singapore; 2021: 1-16
34 Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med 2017; 49 (04) e324-e324
35 Farsetti A, Illi B, Gaetano C. How epigenetics impacts on human diseases. Eur J Intern Med 2023; 114: 15-22
36 Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447 (7147): 972-978
37 Weiterer S, Uhle F, Lichtenstern C. et al. Sepsis induces specific changes in histone modification patterns in human monocytes. PLoS One 2015; 10 (03) e0121748
38 Bomsztyk K, Mar D, An D. et al. Experimental acute lung injury induces multi-organ epigenetic modifications in key angiogenic genes implicated in sepsis-associated endothelial dysfunction. Crit Care 2015; 19 (01) 225
39 Qiao J, Tan Y, Liu H. et al. Histone H3K18 and Ezrin lactylation promote renal dysfunction in sepsis-associated acute kidney injury. Adv Sci (Weinh) 2024; 11 (28) e2307216
40 Liu TF, Yoza BK, El Gazzar M, Vachharajani VT, McCall CE. NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J Biol Chem 2011; 286 (11) 9856-9864
41 Tanemoto F, Mimura I. Therapies targeting epigenetic alterations in acute kidney injury-to-chronic kidney disease transition. Pharmaceuticals (Basel) 2022; 15 (02) 123
42 Xu S, Gao Y, Zhang Q. et al. SIRT1/3 activation by resveratrol attenuates acute kidney injury in a septic rat model. Oxid Med Cell Longev 2016; 2016: 7296092
43 Kawahara TLA, Michishita E, Adler AS. et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009; 136 (01) 62-74
44 Chan C, Li L, McCall CE, Yoza BK. Endotoxin tolerance disrupts chromatin remodeling and NF-kappaB transactivation at the IL-1β promoter. J Immunol 2005; 175 (01) 461-468
45 Hsing CH, Lin CF, So E. et al. α2-Adrenoceptor agonist dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5. Am J Physiol Renal Physiol 2012; 303 (10) F1443-F1453
46 Zhang W, Guan Y, Bayliss G, Zhuang S. Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury. Am J Physiol Renal Physiol 2020; 319 (06) F1015-F1026
47 Zhang Y, Gao Y, Ding Y. et al. Targeting KAT2A inhibits inflammatory macrophage activation and rheumatoid arthritis through epigenetic and metabolic reprogramming. MedComm 2023; 4 (03) e306
48 Li LC. Chromatin remodeling by the small RNA machinery in mammalian cells. Epigenetics 2014; 9 (01) 45-52
49 Ha TY. The role of microRNAs in regulatory T cells and in the immune response. Immune Netw 2011; 11 (01) 11-41
50 Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27 (45) 5959-5974
51 Clark MB, Mattick JS. Long noncoding RNAs in cell biology. Semin Cell Dev Biol 2011; 22 (04) 366-376
52 Scicluna BP, Uhel F, van Vught LA. et al; Molecular Diagnosis and Risk Stratification in Sepsis (MARS) Consortium. The leukocyte non-coding RNA landscape in critically ill patients with sepsis. eLife 2020; 9: e58597
53 Zhu XX, Zheng GL, Lu QB. et al. Cichoric acid ameliorates sepsis-induced acute kidney injury by inhibiting M1 macrophage polarization. Eur J Pharmacol 2024; 976: 176696
54 Chen Y, Jing H, Tang S. et al. Non-coding RNAs in sepsis-associated acute kidney injury. Front Physiol 2022; 13: 830924
55 Quaglia M, Fanelli V, Merlotti G. et al. Dual role of extracellular vesicles in sepsis-associated kidney and lung injury. Biomedicines 2022; 10 (10) 2448
56 Camussi G, Deregibus MC, Cantaluppi V. Role of stem-cell-derived microvesicles in the paracrine action of stem cells. Biochem Soc Trans 2013; 41 (01) 283-287
57 Bettio V, Mazzucco E, Antona A. et al. Extracellular vesicles from human plasma for biomarkers discovery: impact of anticoagulants and isolation techniques. PLoS One 2023; 18 (05) e0285440
58 Deregibus MC, Cantaluppi V, Calogero R. et al. Endothelial progenitor cell derivedmicrovesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007; 110 (07) 2440-2448
59 Mastronardi ML, Mostefai HA, Meziani F, Martínez MC, Asfar P, Andriantsitohaina R. Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress. Crit Care Med 2011; 39 (07) 1739-1748
60 Hu Q, Lyon CJ, Fletcher JK, Tang W, Wan M, Hu TY. Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses. Acta Pharm Sin B 2021; 11 (06) 1493-1512
61 Lv LL, Feng Y, Wu M. et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. Cell Death Differ 2020; 27 (01) 210-226
62 Li ZL, Lv LL, Tang TT. et al. HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation. Kidney Int 2019; 95 (02) 388-404
63 Gildea JJ, Seaton JE, Victor KG. et al. Exosomal transfer from human renal proximal tubule cells to distal tubule and collecting duct cells. Clin Biochem 2014; 47 (15) 89-94
64 Ding H, Zhang L, Yang Q, Zhang X, Li X. Epigenetics in kidney diseases. In: Advances in Clinical Chemistry, Vol. 104. Elsevier; 2021: 233-297
65 Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers 2016; 2 (01) 16045
66 Deng Z, Fan T, Xiao C. et al. TGF-β signaling in health, disease, and therapeutics. Signal Transduct Target Ther 2024; 9 (01) 61
67 Guo C, Pei L, Xiao X. et al. DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8. Kidney Int 2017; 92 (05) 1194-1205
68 Bechtel W, McGoohan S, Zeisberg EM. et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16 (05) 544-550
69 Shindo T, Doi S, Nakashima A, Sasaki K, Arihiro K, Masaki T. TGF-β1 promotes expression of fibrosis-related genes through the induction of histone variant H3.3 and histone chaperone HIRA. Sci Rep 2018; 8 (01) 14060
70 Kim J, Lee H, Yi SJ, Kim K. Gene regulation by histone-modifying enzymes under hypoxic conditions: a focus on histone methylation and acetylation. Exp Mol Med 2022; 54 (07) 878-889
71 Karagiannis D, Rampias T. HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity. Cancers (Basel) 2021; 13 (14) 3575
72 Cao L, Zhu T, Lang X. et al. Inhibiting DNA methylation improves survival in severe sepsis by regulating NF-κB pathway. Front Immunol 2020; 11: 1360
73 Loboda A, Sobczak M, Jozkowicz A, Dulak J. TGF-β1/Smads and miR-21 in renal fibrosis and inflammation. Mediators Inflamm 2016; 2016: 8319283
74 Chau BN, Xin C, Hartner J. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012; 4 (121) 121ra18
75 Zhang Z, Peng H, Chen J. et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett 2009; 583 (12) 2009-2014
76 Zarbock A, Nadim MK, Pickkers P. et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol 2023; 19 (06) 401-417
77 Cantaluppi V, Biancone L, Quercia A, Deregibus MC, Segoloni G, Camussi G. Rationale of mesenchymal stem cell therapy in kidney injury. Am J Kidney Dis 2013; 61 (02) 300-309
78 Gatti S, Bruno S, Deregibus MC. et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 2011; 26 (05) 1474-1483
79 Zhang R, Zhu Y, Li Y. et al. Human umbilical cord mesenchymal stem cell exosomes alleviate sepsis-associated acute kidney injury via regulating microRNA-146b expression. Biotechnol Lett 2020; 42 (04) 669-679
80 Gao F, Zuo B, Wang Y, Li S, Yang J, Sun D. Protective function of exosomes from adipose tissue-derived mesenchymal stem cells in acute kidney injury through SIRT1 pathway. Life Sci 2020; 255: 117719
81 Zhao M, Liu S, Wang C. et al. Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA. ACS Nano 2021; 15 (01) 1519-1538
82 Biancone L, Cantaluppi V, Duò D, Deregibus MC, Torre C, Camussi G. Role of L-selectin in the vascular homing of peripheral blood-derived endothelial progenitor cells. J Immunol 2004; 173 (08) 5268-5274
83 Cantaluppi V, Medica D, Mannari C. et al. Endothelial progenitor cell-derived extracellular vesicles protect from complement-mediated mesangial injury in experimental anti-Thy1.1 glomerulonephritis. Nephrol Dial Transplant 2015; 30 (03) 410-422
84 Zhang Y, Huang H, Liu W. et al. Endothelial progenitor cells-derived exosomal microRNA-21-5p alleviates sepsis-induced acute kidney injury by inhibiting RUNX1 expression. Cell Death Dis 2021; 12 (04) 335
85 Chong CR, Chan WPA, Nguyen TH. et al. Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes. Cardiovasc Drugs Ther 2014; 28 (04) 347-360
86 Fiorentino M, Kellum JA. Improving translation from preclinical studies to clinical trials in acute kidney injury. Nephron 2018; 140 (02) 81-85